[1] Moss C,Kaye SB.Ovarian cancer:progress and continuing controversies in management [J].Eur J Cancer,2002,38(13):1701-7. [2] 杨俊霞,汤为学.DNA修复机制与肿瘤耐药性[J].国外医学·肿瘤学分册,2000,27:352-5. [3] 熊世钢,陈毓仙,吴爱如,等.两株人卵巢癌细胞系(COC1,COC2)的建立及特性[J].中华肿瘤杂志,1993,15(1):22-6.Xiang SG,Chen YX,Wu AR,et al.Establishment and characterization of two human ovarian carcinoma cell lines (COC1,COC2)[J].Chin J Oncol,1993,15(1):22-6. [4] Schena M,Shaion D,Heller R,et al.Parallel human genome analysis:microarray-based expression monitoring of 1000 genes [J].Proc Natl Acad Sci USA,1996,93:10614-9. [5] Vasey PA.Resistance to chemotherapy in advanced ovarian cancer:mechanisms and current strategies[J].Br J Cancer,2003,89(Suppl3):S23-28. [6] Zhong X,Safa AR.RNA helicase A in the MEF1 transcription factor complex up-regulates the MDR1 gene in multidrug-resistant cancer cells[J].J Biol Chem,2004,279(17):17134-41. [7] Fink D,Zheng H,Nebel S,et al.In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair [J].Cancer Res,1997,57(10):1841-5. [8] Drummond JT,Anthoney A,Brown R,et al.Cisplatin and adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line[J].J Biol Chem,1996,271(33):19645-8. [9] Strathdee G,MacKean MJ,Illand M,et al.A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer[J].Oncogene,1999,18(14):2335-41. [10] Chen S,Bigner SH,Modrich P.High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6[J].Proc Natl Acad Sci USA,2001,98(24):13802-7. |